HC Wainwright Reaffirms Buy Rating for KalVista Pharmaceuticals (NASDAQ:KALV)

KalVista Pharmaceuticals (NASDAQ:KALV)‘s stock had its “buy” rating reaffirmed by research analysts at HC Wainwright in a research note issued on Friday,Benzinga reports. They currently have a $20.00 price target on the specialty pharmaceutical company’s stock. HC Wainwright’s price target indicates a potential upside of 103.87% from the company’s current price. HC Wainwright also issued estimates for KalVista Pharmaceuticals’ FY2029 earnings at $1.24 EPS.

Several other research analysts have also weighed in on KALV. Cantor Fitzgerald reiterated an “overweight” rating on shares of KalVista Pharmaceuticals in a research report on Monday, September 9th. Needham & Company LLC reiterated a “buy” rating and set a $28.00 price target on shares of KalVista Pharmaceuticals in a research report on Thursday.

KalVista Pharmaceuticals Price Performance

Shares of KalVista Pharmaceuticals stock opened at $9.81 on Friday. The stock’s 50 day simple moving average is $10.90 and its 200-day simple moving average is $11.82. The stock has a market cap of $423.99 million, a P/E ratio of -2.70 and a beta of 0.85. KalVista Pharmaceuticals has a 1-year low of $7.39 and a 1-year high of $16.88.

KalVista Pharmaceuticals (NASDAQ:KALV) last announced its quarterly earnings data on Thursday, September 5th. The specialty pharmaceutical company reported ($0.87) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.91) by $0.04. As a group, research analysts expect that KalVista Pharmaceuticals will post -2.7 EPS for the current fiscal year.

Insider Activity at KalVista Pharmaceuticals

In other KalVista Pharmaceuticals news, insider Paul K. Audhya sold 8,077 shares of the company’s stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $9.26, for a total transaction of $74,793.02. Following the sale, the insider now owns 94,199 shares in the company, valued at $872,282.74. This represents a 7.90 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Benjamin L. Palleiko sold 14,400 shares of KalVista Pharmaceuticals stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $9.26, for a total transaction of $133,344.00. Following the completion of the transaction, the chief executive officer now owns 266,598 shares of the company’s stock, valued at $2,468,697.48. This represents a 5.12 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 32,016 shares of company stock worth $319,344 in the last three months. 10.50% of the stock is owned by company insiders.

Institutional Investors Weigh In On KalVista Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of KALV. nVerses Capital LLC purchased a new stake in KalVista Pharmaceuticals during the second quarter worth approximately $25,000. China Universal Asset Management Co. Ltd. grew its holdings in shares of KalVista Pharmaceuticals by 67.1% during the third quarter. China Universal Asset Management Co. Ltd. now owns 8,286 shares of the specialty pharmaceutical company’s stock worth $96,000 after purchasing an additional 3,328 shares during the last quarter. Intech Investment Management LLC acquired a new stake in shares of KalVista Pharmaceuticals during the third quarter worth about $126,000. SG Americas Securities LLC acquired a new stake in shares of KalVista Pharmaceuticals in the 3rd quarter valued at about $153,000. Finally, Quest Partners LLC purchased a new position in KalVista Pharmaceuticals during the 3rd quarter worth approximately $175,000.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).